



drug development from bench 2 bedside

CASE STUDY





OUR CLIENT

Our client, an academic research group, needed to explore the *in vivo* therapeutic potential of a novel small molecule as an inovative treatment strategy for triple negative breast cancer (TNBC).

The client already obtained promising *in vitro* results and needed to complement them with an *in vivo* approach.



GOALS

- Check the ability of the molecule to treat triple negative breast cancer in vivo.
- Evaluation of the compound protection against on tumor metastasis.
- Evaluation of any possible adverse effects occurring during the treatment course.



STRATEGY

Use an *in vivo* model of human TNBC to confirm and obtain significant data.

Analysing results and providing clients with strategic insights to enhance their chances of obtaining better results and reach the pharmaceutical market.

MAIN QUESTION

Is the potential therapeutic agent efficient in targeting triple negative breast cancer?

Our Advantages



Access to a team of specialists with a deep understanding of the TNBC *in vivo* model ensuring a comprehensive evaluation of the therapeutic agent's efficacy.



Assistance in designing a robust and eficient experimental protocol, maximizing the scientific value of the study while minimizing unnecessary complexities.



Continued support in the interpretation of study results and assistance in **planning subsequent phases or adapting strategies** based on the outcomes.